SCHEMBL6014907

SCHEMBL6014907

COc1ccc(-c2cc(-c3ccccn3)nn(-c3ccccc3Br)c2=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 2/20 0.48
GABRB3 P28472 2/20 0.48
GABRA3 P34903 2/20 0.48
DCTPP1 Q9H773 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
NPC1 O15118 1/20 0.42
HSP90AA1 P07900 1/20 0.42
PKM P14618 1/20 0.42
RAB9A P51151 1/20 0.42
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GABRA1 P14867 1/20 0.41
GABRA2 P47869 1/20 0.41
KDR P35968 1/20 0.40
TGFBR1 P36897 2/20 0.40
SLC11A2 P49281 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6014849 0.89 MEN1 (0.48) DCTPP1L3MBTL1NPC1PKMRAB9A
SCHEMBL6014843 0.87 DCTPP1 (0.40) DCTPP1L3MBTL1NPC1RAB9AMAPT
SCHEMBL6014852 0.85 TGFBR1 (0.46) MAPTTGFBR1ALDH1A1MEN1KMT2A
SCHEMBL28775311 0.83 DCTPP1 (0.45) DCTPP1L3MBTL1NPC1PKMRAB9A
SCHEMBL27755586 0.83 LMNA (0.48) DCTPP1L3MBTL1NPC1PKMRAB9A
SCHEMBL6014894 0.81 MAPT (0.38) DCTPP1L3MBTL1NPC1RAB9AMAPT
SCHEMBL6014840 0.80 CYP2A6 (0.49) DCTPP1NPC1PKMRAB9AMAPT
SCHEMBL6014873 0.79 DCTPP1 (0.45) DCTPP1L3MBTL1NPC1PKMRAB9A
SCHEMBL6014861 0.77 DCTPP1 (0.38) DCTPP1METAP1LMNA
SCHEMBL6014954 0.77 TGFBR1 (0.48) MAPTTGFBR1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060189622-A1 Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-08-24 US claimed
EP-1319659-A1 PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF Eisai Co., Ltd. (JP) 2003-06-18 EP claimed
US-20060189622-A1 Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-08-24 US disclosed
EP-1319659-A1 PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF Eisai Co., Ltd. (JP) 2003-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189622-A1 Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations GRIK3, GRIK1, GRIK2 GABRG2 146/4885GABRB3 102/4885GABRA3 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.